Search results for "INTERFERON"

showing 10 items of 963 documents

Osteodystrophy in chronic liver diseases

2013

Osteoporosis and osteomalacia are, to date, among the most common metabolic diseases in the world. Lately, an association between metabolic bone diseases and chronic liver disease has been increasingly reported, inducing many authors to create a new nosographic entity known as 'hepatic osteodystrophy.' The importance of such a condition is further increased by the morbidity of these two diseases, which greatly reduce the quality of life because of frequent fractures, especially vertebral and femoral neck ones. For this reason, early identification of high-risk patients should be routinely performed by measuring bone mass density. The explanation for the association between bone diseases and…

Pediatricsmedicine.medical_specialtyPathologySettore MED/09 - Medicina InternaOsteoporosisInterferon therapychronic liver diseasesChronic liver diseaseBone DensityRisk FactorsInternal MedicinemedicineHumansOsteodystrophyFrequent fracturesFemoral neckOsteomalaciaDiphosphonatesbusiness.industryLiver Diseasesmedicine.diseaseOsteodystrophyBone Diseases Metabolicmedicine.anatomical_structureChronic DiseaseOsteomalaciaQuality of LifeEmergency MedicineBone mass densityOsteoporosisOsteodystrophy; chronic liver diseasesbusinessInternal and Emergency Medicine
researchProduct

Individualized treatment with combination of Peg-interferon alpha 2b and ribavirin in patients with HCV genotype 3

2010

Background & Aims: The benefit of individualizing treatment for patients with genotype 3 HCV infection on the basis of viral clearance at week 4 (wk4-R) has not been firmly established. Methods: Four hundred and fourteen patients received Peginterferon alpha-2b plus 1000–1200 mg of ribavirin daily according with body weight > or <75 kg. Patients were randomized to standard 24 weeks (Std24) or to a 12 or 36 weeks variable treatment duration (Var12/36). In the variable treatment arm, patients with or without wk4-R were allocated to either 12 or 36 weeks duration. Results: At treatment week 4, HCV RNA was undetectable in 262 patients (63.3%), 136 in the Std24, and 126 in the Var12/36 group (p …

Peg-interferonRibavirinHCV genotype 3Short treatment
researchProduct

Expression of membrane C1q in human monocyte-derived macrophages is developmentally regulated and enhanced by interferon-γ

2001

The present study investigated when during "in vitro" maturation macrophages (MPhi) express membrane C1q (mC1q), and whether cell activation affects expression and function of mC1q. Although C1q mRNA was repeatedly detected in freshly isolated monocytes using reverse transcriptase-polymerase chain reaction, C1q protein was observed only in developing MPhi from day 1 to 4 on using immunodetection and flow cytometry. However, the quantity of mC1q and other MPhi membrane proteins differed strikingly in cells from different donors. We report here for the first time that CD14(+) and CD14(-) mC1q-bearing MPhi can develop, and that interferon-gamma increases mC1q display at the cell surface, and m…

PhagocytosisCD14CellLipopolysaccharide ReceptorsBiophysicsMonocyte/macrophageComplementEnzyme-Linked Immunosorbent AssayBiologyLymphocyte ActivationBiochemistryFlow cytometryInterferon-gammaPhagocytosisStructural BiologyGeneticsmedicineHumansMolecular BiologyCells CulturedC1qMessenger RNAmedicine.diagnostic_testComplement C1qMacrophagesCell DifferentiationCell BiologyFlow CytometryPrecipitin TestsMolecular biologyIn vitromedicine.anatomical_structureGene Expression RegulationMembrane proteinDifferentiationCell activationFEBS Letters
researchProduct

Synergy assessment of fixed combinations of Herba Andrographidis and Radix Eleutherococci extracts by transcriptome-wide microarray profiling

2015

Abstract Background Generally accepted, but insufficiently proved, the concept of synergy is based on an assumption that combining of two biologically active substances is justified because the combination is more active and less harmful than the ingredients. Hypothesis Analysis of RNA microarray of isolated neuroglia cells and the comparison the number of genes deregulated by plant extracts and their fixed herbal formulation might be a useful tool/method for assessment of synergistic and antagonistic interactions of herbal extracts in human organism. Aim The primary aim of this study was to extend a new method of assessment of synergistic and antagonistic interactions of herbal extracts in…

Pharmaceutical ScienceEleutherococcusComputational biologyPharmacologyBiologyVenn diagramsPlant RootsCell LineTranscriptomeInterferonAcanthaceaeDrug DiscoverymedicineHumansAraliaceaeGenePharmacologyRegulation of gene expressionPlant ExtractsMicroarray analysis techniquesGene Expression ProfilingDrug SynergismMicroarray AnalysisFold changeGene expression profilingSynergyGene Expression RegulationComplementary and alternative medicineMolecular MedicineAndrographisSignal transductionPharmacogenomicsNeurogliaNetwork pharmacologymedicine.drugPhytomedicine
researchProduct

Effects of gamma interferon on a B16 melanoma cell line and its doxorubicin-resistant variant.

1992

PharmacologyDoxorubicin resistantbusiness.industryDrug ResistanceMelanoma ExperimentalBiologyVirologyMajor Histocompatibility ComplexInterferon-gammaText miningCell cultureAntigens NeoplasmDoxorubicinGamma interferonTumor Cells CulturedbusinessB16 melanomaPharmacological research
researchProduct

Ganodermycin, a novel inhibitor of CXCL10 expression from Ganoderma applanatum

2011

CXCL10 (inducible protein-10) is a highly inducible chemoattractant, which contributes to the recruitment of inflammatory cells, such as macrophages and T-lymphocytes, and thereby has important roles in chronic inflammatory conditions. In a search for new inhibitors of CXCL10 expression in MonoMac6 cells, a novel compound, designated as Ganodermycin, was isolated from fermentations of the basidiomycete Ganoderma applanatum. The structure was determined by a combination of spectroscopic techniques. Ganodermycin inhibited the lipopolysaccharide (LPS)/interferon (IFN)-γ-induced CXCL10 promoter activity in transiently transfected MonoMac6 cells in a dose-dependent manner with IC(50) values of 1…

PharmacologyLipopolysaccharidebiologyGanodermaChemotaxisTransfectionPharmacologybiology.organism_classificationMolecular biologychemistry.chemical_compoundGanoderma applanatumchemistryInterferonDrug DiscoveryProtein biosynthesismedicineCXCL10medicine.drugThe Journal of Antibiotics
researchProduct

Rhabdomyolysis associated with the co-administration of daptomycin and pegylated interferon  -2b and ribavirin in a patient with hepatitis C

2011

PharmacologyMicrobiology (medical)business.industryRibavirinPegylated interferon αHepatitis CPharmacologymedicine.diseasechemistry.chemical_compoundInfectious DiseaseschemistryMedicinePharmacology (medical)DaptomycinbusinessRhabdomyolysisCo administrationmedicine.drugJournal of Antimicrobial Chemotherapy
researchProduct

Expression of the human complement C8 subunits is independently regulated by interleukin 1β, interleukin 6, and interferon γ

1998

The eighth component of human complement (C8) is composed of two subunits which are products from three separate genes. The alpha-gamma- and the beta-subunit of C8 are expressed independently, and are part of the membrane attack complex. C8 is primarily synthesized in the liver. It has been shown in previous studies that the human hepatoma cell line HepG2 constitutively expresses C8, and thus is a suitable model system for studying C8 biosynthesis in vitro. Expression is modulated by the cytokines IL-1 beta, IL-6 and IFN-gamma. The effect of the different cytokines on the expression of these subunits was examined using biosynthetical labelling and immunoprecipitation methods. C8 alpha-gamma…

PharmacologybiologyInterleukin-6ImmunoprecipitationAntineoplastic AgentsSulfur RadioisotopesComplement C8Precipitin TestsMolecular biologyIn vitroComplement systemInterferon-gammaGene expressionTumor Cells Culturedbiology.proteinHumansSecretionInterleukin 6Beta (finance)Complement membrane attack complexInterleukin-1Immunopharmacology
researchProduct

Increased Percentages of Tumor Necrosis Factor-α+/Interferon-T+Lymphocytes and Calprotectin+/Tumor Necrosis Factor-A+ Monocytes in Patients with Acut…

2012

In vivo exposure to microorganisms resident in the oral cavity is considered as a possible cause of Kawasaki disease (KD), and some epitopes derived from streptococci display homology with Factor H of Complement. Additionally, calprotectin, a major calcium binding protein released by neutrophils and activated monocytes, could be directly involved in endothelial damage occurring in KD. The aim of our study is to evaluate the percentages of IFN-γ+ and/or TNF-α+ lymphocytes and double positive calprotectin/TNF-α monocytes (CD14+) after in vitro stimulation with streptococcal- and/or Factor H-derived peptides, in patients with acute KD. Peripheral Blood Mononuclear Cells (PBMCs) obtained from …

Pharmacologybusiness.industryImmunologymedicine.diseaseEpitopeInterferonIn vivoImmunologymedicineImmunology and AllergyIn patientKawasaki diseaseTumor necrosis factor alphaCalprotectinbusinessTumor necrosis factor αmedicine.drugInternational Journal of Immunopathology and Pharmacology
researchProduct

Interferon-?? Alone versus Interferon-?? plus Ribavirin in Patients with Chronic Hepatitis C Not Responding to Previous Interferon-?? Treatment

2000

Objective: To study the effects of monotherapy with leucocyte interferon-α (IFNα) versus IFNα + ribavirin in patients with chronic hepatitis C who were nonresponders to previous courses of recombinant or lymphoblastoid IFNα. Design and setting: This was a nonblind randomised study of outpatients at 3 centres in Palermo, Sicily, Italy. Patients and participants: We recruited 72 patients (48 males, 24 females), mean age 48.8 ± 6.6 years (range 31 to 63 years), with biopsy-proven chronic hepatitis C, predominantly genotype lb. Interventions: 24 patients (group A) received IFNα 6MU 3 times weekly for 6 months, and 48 patients (group B) received IFNα 6MU 3 times weekly + ribavirin 1200 mg/day fo…

Pharmacologymedicine.medical_specialtyCombination therapybusiness.industryRibavirinHepatitis C virusAlpha interferonGeneral Medicinemedicine.disease_causeGastroenterologydigestive system diseasesGroup Bchemistry.chemical_compoundchemistryInterferonInternal medicineAbsolute neutrophil countMedicinePharmacology (medical)businessAdverse effectBiotechnologymedicine.drugBioDrugs
researchProduct